Global Vasculitis Treatment Market 2017-2021

  • Published: Jun 2017
  • Pages: 78
  • SKU: IRTNTR13490

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This market research study identifies Bristol-Myers Squibb, CELGENE, F. Hoffmann-La Roche, and GlaxoSmithKline as the leading players in the global vasculitis treatment market. A comprehensive analysis of this market is also presented by drug class (corticosteroids, immunosuppressants, and biologics) and by geography (the Americas, APAC, and EMEA).

Overview of the global vasculitis treatment market

According to vasculitis treatment industry insights, the global vasculitis treatment market will grow at a CAGR of more than 4% during the forecast period. The provision for special drug designations is one of the key drivers that will stimulate growth in the market from 2017 to 2021. The regulatory authorities of the US and Europe have listed vasculitis as one of the rare diseases because it involves a limited patient population. This prevents the recovery of expenses that are invested in research and developmental activities for the treatment of vasculitis. As a result, the US and the European Union (EU) provide provisions for orphan drug designation of drugs to overcome this limitation. In the US, orphan drugs are offered incentives such as tax credits for clinical testing, exemption from prescription fees, and market exclusivity for seven years. To protect the sales of orphan drugs, the entry of generics is barred for the duration of market exclusivity. The orphan drug designation and approvals in Japan involves incentives in the form of financial aid. These incentives cover the costs of clinical trials and tax exemptions of up to 6% of research costs and 10% of corporate tax. These provisions will encourage manufacturers to develop novel therapies for vasculitis in the forthcoming years.

One of the key vasculitis treatment market trends that will gain traction in the vasculitis treatment market is the increase in public awareness programs. These programs develop the best-individualized treatment plan for each patient to offer an advanced care for patients with vasculitis. Also, these programs will increase awareness about autoimmune diseases, such as vasculitis, which in turn, will positively impact the market’s growth.

Competitive landscape and key vendors

The vasculitis treatment market is characterized by the presence of a few key vendors and is highly concentrated. These vendors are increasingly competing against each other based on factors such as new disease indication. The development of drugs for the treatment of RA, psoriatic arthritis, and psoriasis will strengthen the competitive environment of the market.

Key vendors in this market are 

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • GlaxoSmithKline

Other prominent vendors in the market include Ablynx, AB SCIENCES, Acorda Therapeutics, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, AstraZeneca, Baxter, Boehringer Ingelhein, Can-Fite BioPharma, Celltrion, ChemoCentryx, Coherus BioSciences, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Hospira, Idera, Immunomedics, ImmuPharma, Incyte, Invion, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, MedImmune, Morphotek, Novo Nordisk, Novartis, Opexa Therapeutics, Principia, Regeneron, Sandoz, Sanofi, Santarus, Takeda, UCB, Vaccinex, Vertex Pharmaceuticals, and Vitae Pharmaceuticals.

Segmentation by drug class and analysis of the vasculitis treatment market

  • Corticosteroids
  • Immunosuppressants
  • Biologics

Biologics are large molecules that are extracted from biological sources such as humans, animals, or microorganisms. The segment is growing at a rapid pace due to the increased uptake of these drugs in developed markets such as the US and Europe. The segment will continue to grow until the end of 2021 as it includes a wide range of products such as gene therapy, recombinant proteins, somatic cells, tissues, and vaccines to treat various diseases.

Segmentation by geography and analysis of the vasculitis treatment market

  • Americas
  • APAC
  • EMEA

Based on the vasculitis treatment market outlook, the Americas accounted for the majority of market shares during 2016 due to the growing incidence of rheumatoid vasculitis. Rheumatoid vasculitis affects the small and medium-sized blood vessels in patients. The region will continue to be accountable for the largest shares for the next four years due to the increasing demand for drugs for the treatment of rheumatoid arthritis (RA) and giant cell arteritis (GCA).

Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global vasculitis treatment market?
  • What are the key market trends impacting the growth of the global vasculitis treatment market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global vasculitis treatment market?
  • What are the market opportunities and threats faced by the vendors in the global vasculitis treatment market?
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
  • What are the key outcomes of the five forces analysis of the global vasculitis treatment market?

Technavio also offers customization on reports based on specific client requirement.


PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Pipeline landscape

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Market segmentation by drug class

  • Corticosteroids
  • Immunosuppressants
  • Biologics

PART 08: Geographical segmentation

  • Vasculitis treatment market in Americas
  • Vasculitis treatment market in EMEA
  • Vasculitis treatment market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges

PART 11: Market trends

  • Increase in public awareness programs
  • Strategic alliances
  • Introduction of novel MOAs

PART 12: Vendor landscape

  • Competitive scenario
  • Key vendor analysis
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Other prominent vendors

PART 13: Appendix

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>